Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhoenix Group Holdings Regulatory News (PHNX)

  • There is currently no data for PHNX

Internal Model Harmonisation Approval

14 Sep 2021 14:07

RNS Number : 7533L
Phoenix Group Holdings PLC
14 September 2021
 

LEI: 2138001P49OLAEU33T68

 

Phoenix Group's Internal Model Harmonisation application is approved by the PRA

 

The Board of Phoenix Group Holdings plc ("the Group") is pleased to announce that the Prudential Regulation Authority ("PRA") has approved its application to harmonise its legacy Phoenix and Standard Life internal models.

 

This single, more sophisticated harmonised Internal Model will provide deeper insights into our risk profile which further strengthens the Group's risk management approach and decision making, as well as delivering significant capital synergies through diversification and improved risk modelling.

 

The harmonised Internal Model will go live effective 30 September 2021 and is currently estimated to increase the Group's Solvency II ("SII") Surplus by c.£0.4 billion. It is expected that c.£0.1 billion of the increased SII Surplus will then emerge as an acceleration of cash in 2022, after an appropriate period of operation.

 

The harmonised Internal Model also delivers a reduced capital strain for the Group's Bulk Purchase Annuity ("BPA") new business and unlocks a wider pipeline of future management actions including the execution of Part VIIs, the delivery of further enhancements to the Group's credit risk modelling capabilities and the foundation to bring ReAssure onto the new Internal Model in time. It will also support the Group in delivering future value accretive M&A.

 

-------------------------------------------------------------------------------------------------------------------------------------------------------

Enquiries

Investors/analysts:

Claire Hawkins, Director of Corporate Affairs, Phoenix Group

+44 (0)20 3735 0575

Andrew Downey, Investor Relations Director, Phoenix Group

+44 (0)20 3735 0160

Media:

Douglas Campbell, Teneo

+44 (0)775 313 6628

Shellie Wells, Corporate Communications Director, Phoenix Group

+44 (0)20 3735 0922

-------------------------------------------------------------------------------------------------------------------------------------------------------

Legal Disclaimers

This announcement in relation to Phoenix and its subsidiaries (the "Group") contains forward-looking statements about the Group's current plans, goals and expectations relating to future financial events, conditions, performance, results, strategy and/or objectives. Statements containing the words: 'believes', 'intends', 'will', 'expects', 'may', 'should', 'plans', 'aims', 'seeks', 'continues', 'targets' and 'anticipates' or other words of similar meaning are forward-looking. Such forward-looking statements involve risk and uncertainty because they relate to future events and circumstances that are beyond the Group's control. As a result, such future events and the Group's actual future financial condition, performance and results may differ materially from the plans, goals and expectations set out in the forward-looking statements in this announcement. The Group undertakes no obligation to update any of the forward-looking statements contained within this announcement. References in this announcement to Solvency II Surplus should be read in conjunction with the relevant footnotes set out in the 2021 Half Year Results Announcement of 11 August 2021.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAGZGMLFDDGMZM
Date   Source Headline
3rd Jul 20233:30 pmRNSTotal Voting Rights
30th Jun 202311:30 amRNSPublication of a Prospectus
16th Jun 20233:01 pmRNSDirector Declaration
12th Jun 20231:30 pmRNSBlock Listing Return
7th Jun 20238:38 amRNSDirector/PDMR Shareholding
1st Jun 20231:24 pmRNSBlock Listing Application
1st Jun 20231:00 pmRNSTotal Voting Rights
16th May 202312:10 pmRNSDirector/PDMR Shareholding
11th May 20236:00 pmRNSDirectorate Change
10th May 20234:06 pmRNSDirector/PDMR Shareholding
4th May 20233:35 pmRNSHolding(s) in Company
4th May 20232:19 pmRNSResult of AGM
2nd May 20233:00 pmRNSTotal Voting Rights
6th Apr 20233:00 pmRNSDirector/PDMR Shareholding
3rd Apr 20235:30 pmRNSDirector/PDMR Shareholding
3rd Apr 20235:30 pmRNSDirector/PDMR Shareholding
3rd Apr 20235:30 pmRNSTotal Voting Rights
3rd Apr 20238:02 amRNSAcquisition
30th Mar 20232:00 pmRNSDirector/PDMR Shareholding
28th Mar 20234:30 pmRNSDirector/PDMR Shareholding
23rd Mar 20233:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20235:45 pmRNSNotice of AGM
22nd Mar 20233:00 pmRNSDirector/PDMR Shareholding
20th Mar 20235:00 pmRNSDirector/PDMR Shareholding
15th Mar 20235:30 pmRNSDirector/PDMR Shareholding
13th Mar 20233:00 pmRNSDirector/PDMR Shareholding
13th Mar 20237:00 amRNS2022 Annual Financial Report
10th Mar 20239:31 amRNSDirectorate Change - Replacement
10th Mar 20239:00 amRNSDirectorate Change
8th Mar 20234:00 pmRNSDirector/PDMR Shareholding
1st Mar 20232:00 pmRNSTotal Voting Rights
7th Feb 20233:45 pmRNSMiscellaneous - PGH/TCS Extension of Partnership
7th Feb 20232:30 pmRNSDirector/PDMR Shareholding
1st Feb 20232:00 pmRNSTotal Voting Rights
6th Jan 20234:30 pmRNSDirector/PDMR Shareholding
30th Dec 20221:00 pmRNSTotal Voting Rights
12th Dec 20224:30 pmRNSBlock listing Interim Review
7th Dec 20224:45 pmRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSTrading Statement
30th Nov 20222:00 pmRNSTotal Voting Rights
8th Nov 20225:30 pmRNSDirector/PDMR Shareholding
31st Oct 20226:00 pmRNSTotal Voting Rights
12th Oct 20224:00 pmRNSDirectorate Change
6th Oct 20224:30 pmRNSDirector/PDMR Shareholding
6th Oct 20224:30 pmRNSDirector/PDMR Shareholding
4th Oct 20224:30 pmRNSHolding(s) in Company
4th Oct 20227:00 amRNSDirector/PDMR Shareholding
30th Sep 20224:30 pmRNSTotal Voting Rights
14th Sep 20224:30 pmRNSDirector/PDMR Shareholding
9th Sep 202211:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.